[Role of allogeneic transplantation of bone marrow in juvenile chronic myelomonocytic leukemia].
Two boys with clinical and haematological evidence of juvenile chronic myelomonocytic leukaemia had no chromosomal anomaly. In addition, one presented with an unbalanced Epstein-Barr virus serology, and the other with xantholeukaemia. Allogenic bone marrow transplantation was performed in the first boy after an 18-month period during which treatment with 6-mercaptopurine, intensive chemotherapy and splenectomy had failed. Conditioning included cyclophosphamide, high-dose cytarabine and whole-body irradiation. There was no complication, and 16 months after transplantation the patient was in complete remission. The second boy received a bone marrow transplant on the 6th month of the disease, after failure of 6-mercaptopurine. Conditioning included etoposide, busulfan and cyclophosphamide. On the 35th post-transplantation day the child had severe pancytopenia and his spleen remained enlarged. A second transplantation was performed after treatment with melphalan and whole-body irradiation. Twelve months later, the patient was in complete remission. The indications and modalities of allogenic bone marrow transplantation in juvenile chronic myelomonocytic leukaemia and the value of pre-transplantation splenectomy are discussed.
Lutz
P
P
Service de Pédiatrie 4, Institut de Puériculture, Hospices Civils, Strasbourg.
Folléa
G
G
Albert
A
A
Falkenrodt
A
A
Jung
J J
JJ
Masson
E
E
Lévy
J M
JM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007223:Infant; D015477:Leukemia, Myelomonocytic, Chronic / Q000628:therapy*; D008297:Male; D012074:Remission Induction; D013156:Splenectomy; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
Place de la greffe allogénique de moelle osseuse dans la leucémie myélomonocytaire chronique juvénile.